NASDAQ:OPGN - OpGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.91 +0.08 (+4.37 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$1.91
Today's Range$1.8507 - $2.02
52-Week Range$1.62 - $20.00
Volume419,031 shs
Average Volume482,930 shs
Market Capitalization$10.40 million
P/E Ratio-0.20
Dividend YieldN/A
Beta1.3

About OpGen (NASDAQ:OPGN)

OpGen logoOpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260

Debt

Debt-to-Equity Ratio0.03
Current Ratio2.45
Quick Ratio2.35

Price-To-Earnings

Trailing P/E Ratio-0.20
Forward P/E Ratio-0.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.21 million
Price / Sales3.55
Cash FlowN/A
Price / CashN/A
Book Value$1.56 per share
Price / Book1.22

Profitability

EPS (Most Recent Fiscal Year)($9.78)
Net Income$-15,410,000.00
Net Margins-409.83%
Return on Equity-437.11%
Return on Assets-152.04%

Miscellaneous

Employees43
Outstanding Shares5,960,000

OpGen (NASDAQ:OPGN) Frequently Asked Questions

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

How were OpGen's earnings last quarter?

OpGen (NASDAQ:OPGN) posted its quarterly earnings data on Tuesday, May, 8th. The medical research company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.84) by $0.09. The medical research company earned $0.85 million during the quarter, compared to the consensus estimate of $0.74 million. OpGen had a negative net margin of 409.83% and a negative return on equity of 437.11%. View OpGen's Earnings History.

When is OpGen's next earnings date?

OpGen is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for OpGen.

What price target have analysts set for OPGN?

2 Wall Street analysts have issued twelve-month price targets for OpGen's shares. Their predictions range from $9.00 to $9.00. On average, they expect OpGen's share price to reach $9.00 in the next twelve months. View Analyst Ratings for OpGen.

Who are some of OpGen's key competitors?

Who are OpGen's key executives?

OpGen's management team includes the folowing people:
  • Mr. Evan Jones, Chairman & CEO (Age 61)
  • Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 59)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 47)
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 59)
  • Mr. Michael Farmer, Director of Marketing

When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

Has OpGen been receiving favorable news coverage?

Media coverage about OPGN stock has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OpGen earned a news sentiment score of 0.02 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.83 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.91.

How big of a company is OpGen?

OpGen has a market capitalization of $10.40 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]


MarketBeat Community Rating for OpGen (OPGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OpGen (NASDAQ:OPGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for OpGen in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 371.20%. The high price target for OPGN is $9.00 and the low price target for OPGN is $9.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$25.00
Price Target Upside: 371.20% upside402.79% upside258.57% upside251.99% upside

OpGen (NASDAQ:OPGN) Consensus Price Target History

Price Target History for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ:OPGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018HC WainwrightSet Price TargetBuy$9.00HighView Rating Details
6/19/2017Dawson JamesReiterated RatingBuyLowView Rating Details
8/10/2016Rodman & RenshawSet Price TargetBuy$82.50N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

OpGen (NASDAQ:OPGN) Earnings History and Estimates Chart

Earnings by Quarter for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ:OPGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.38 EPS
Next Year EPS Consensus Estimate: $-1.45 EPS

OpGen (NASDAQ OPGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.58)N/AView Earnings Details
5/8/2018Q1 2018($0.84)($0.75)$0.74 million$0.85 millionViewN/AView Earnings Details
3/15/2018Q4 2017($1.38)($1.33)$0.81 million$0.99 millionViewN/AView Earnings Details
11/7/2017Q3 2017($2.00)($1.75)$0.86 million$0.75 millionViewN/AView Earnings Details
8/8/2017Q2 2017($4.00)($3.75)$0.82 million$0.70 millionViewN/AView Earnings Details
4/26/2017Q1 2017($3.75)($4.75)$1.03 million$0.77 millionViewN/AView Earnings Details
3/23/2017Q4 2016($5.00)($5.25)$1.00 million$1.01 millionViewN/AView Earnings Details
10/24/2016Q3($6.75)($5.75)$1.10 million$0.73 millionViewListenView Earnings Details
8/9/2016Q2 2016($7.00)($9.25)$1.10 million$1.18 millionViewN/AView Earnings Details
5/12/2016Q1($7.50)($9.00)$1.10 millionViewListenView Earnings Details
3/30/2016Q4($9.50)$1.33 millionViewListenView Earnings Details
11/12/2015Q315($9.50)$0.98 millionViewListenView Earnings Details
8/13/2015Q215($21.00)$1.10 million$0.38 millionViewListenView Earnings Details
6/17/2015Q115($140.25)$0.47 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OpGen (NASDAQ:OPGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OpGen (NASDAQ OPGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.83%
Institutional Ownership Percentage: 13.10%
Insider Trading History for OpGen (NASDAQ:OPGN)
Institutional Ownership by Quarter for OpGen (NASDAQ:OPGN)

OpGen (NASDAQ OPGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/18/2017Jven Capital, LlcChairmanBuy1,875,000$0.40$750,000.00View SEC Filing  
7/18/2017Timothy C DecCFOBuy65,000$0.40$26,000.00118,966View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OpGen (NASDAQ OPGN) News Headlines

Source:
DateHeadline
Reviewing OpGen (OPGN) and Foundation Medicine (FMI)Reviewing OpGen (OPGN) and Foundation Medicine (FMI)
www.americanbankingnews.com - May 18 at 11:25 PM
Financial Contrast: Foundation Medicine (FMI) & OpGen (OPGN)Financial Contrast: Foundation Medicine (FMI) & OpGen (OPGN)
www.americanbankingnews.com - May 15 at 1:22 AM
OPGEN, INC.OPGEN, INC.
www.streetinsider.com - May 14 at 5:24 PM
BRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of 1.05 mln Shares Of Cos Common StockBRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of 1.05 mln Shares Of Co's Common Stock
www.reuters.com - May 14 at 5:24 PM
BRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of Up To 2.7 Million Shares Of Common StockBRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of Up To 2.7 Million Shares Of Common Stock
www.reuters.com - May 14 at 5:24 PM
Reviewing OpGen (OPGN) & RadNet (RDNT)Reviewing OpGen (OPGN) & RadNet (RDNT)
www.americanbankingnews.com - May 12 at 1:24 PM
Zacks Investment Research Lowers OpGen (OPGN) to SellZacks Investment Research Lowers OpGen (OPGN) to Sell
www.americanbankingnews.com - May 12 at 10:38 AM
Edited Transcript of OPGN earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of OPGN earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 6:03 PM
OpGen (OPGN) Releases Quarterly  Earnings Results, Beats Expectations By $0.09 EPSOpGen (OPGN) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - May 10 at 5:32 PM
Biocept (BIOC) vs. OpGen (OPGN) Critical AnalysisBiocept (BIOC) vs. OpGen (OPGN) Critical Analysis
www.americanbankingnews.com - May 10 at 10:58 AM
HC Wainwright Analysts Give OpGen (OPGN) a $9.00 Price TargetHC Wainwright Analysts Give OpGen (OPGN) a $9.00 Price Target
www.americanbankingnews.com - May 9 at 5:12 PM
OpGens (OPGN) CEO Evan Jones on Q1 2018 Results - Earnings Call TranscriptOpGen's (OPGN) CEO Evan Jones on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:14 AM
OpGen Reports First Quarter 2018 Financial Results and Provides a Business UpdateOpGen Reports First Quarter 2018 Financial Results and Provides a Business Update
finance.yahoo.com - May 8 at 5:45 PM
ValuEngine Upgrades OpGen (OPGN) to "Hold"ValuEngine Upgrades OpGen (OPGN) to "Hold"
www.americanbankingnews.com - May 2 at 10:58 PM
OpGen Announces Date of First Quarter 2018 Financial Results Conference CallOpGen Announces Date of First Quarter 2018 Financial Results Conference Call
finance.yahoo.com - May 1 at 5:21 PM
Analyzing OpGen (OPGN) and Cancer Genetics (CGIX)Analyzing OpGen (OPGN) and Cancer Genetics (CGIX)
www.americanbankingnews.com - April 27 at 11:27 PM
OpGen (OPGN) Presents Acuitas Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug ...OpGen (OPGN) Presents Acuitas Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug ...
www.streetinsider.com - April 25 at 5:33 PM
HC Wainwright Reiterates "$9.00" Price Target for OpGen (OPGN)HC Wainwright Reiterates "$9.00" Price Target for OpGen (OPGN)
www.americanbankingnews.com - April 25 at 9:58 AM
OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug ...OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug ...
globenewswire.com - April 24 at 5:38 PM
With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like MoveWith FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move
finance.yahoo.com - April 20 at 8:19 AM
US STOCKS ON THE MOVE-Philip Morris, AmEx, Amazon, P&G, ChannelAdvisorUS STOCKS ON THE MOVE-Philip Morris, AmEx, Amazon, P&G, ChannelAdvisor
www.nasdaq.com - April 19 at 5:45 PM
OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International OperationsOpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
finance.yahoo.com - April 19 at 5:45 PM
This Mornings Technical Outlook on Medical Research Stocks -- Invitae, IQVIA, Laboratory Corp., and OpGenThis Morning's Technical Outlook on Medical Research Stocks -- Invitae, IQVIA, Laboratory Corp., and OpGen
www.prnewswire.com - April 17 at 8:24 AM
OpGen (OPGN) Set to Announce Quarterly Earnings on TuesdayOpGen (OPGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 17 at 4:11 AM
Comparing Genomic Health (GHDX) & OpGen (OPGN)Comparing Genomic Health (GHDX) & OpGen (OPGN)
www.americanbankingnews.com - April 16 at 1:21 AM
HC Wainwright Analysts Give OpGen (OPGN) a $25.00 Price TargetHC Wainwright Analysts Give OpGen (OPGN) a $25.00 Price Target
www.americanbankingnews.com - April 11 at 11:52 PM
OpGen (OPGN) Downgraded to "Hold" at Zacks Investment ResearchOpGen (OPGN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:52 AM
OpGen (OPGN) Upgraded to "Buy" by Zacks Investment ResearchOpGen (OPGN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:01 PM
OpGen (OPGN) Rating Reiterated by HC WainwrightOpGen (OPGN) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 5 at 9:36 PM
Critical Survey: OpGen (OPGN) versus Magellan Health (MGLN)Critical Survey: OpGen (OPGN) versus Magellan Health (MGLN)
www.americanbankingnews.com - March 29 at 3:34 PM
HC Wainwright Boosts OpGen (OPGN) Price Target to $9.00HC Wainwright Boosts OpGen (OPGN) Price Target to $9.00
www.americanbankingnews.com - March 25 at 8:16 AM
OpGen (OPGN) Given a $9.00 Price Target by HC Wainwright AnalystsOpGen (OPGN) Given a $9.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 16 at 7:46 PM
OpGens (OPGN) CEO Evan Jones on Q4 2017 Results - Earnings Call TranscriptOpGen's (OPGN) CEO Evan Jones on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 6:33 PM
Edited Transcript of OPGN earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of OPGN earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:33 PM
OpGen Reports Fourth Quarter and Full Year 2017 Financial Results ... - GlobeNewswire (press release)OpGen Reports Fourth Quarter and Full Year 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:14 AM
OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business UpdateOpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
finance.yahoo.com - March 15 at 6:17 PM
Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® TestsWired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests
finance.yahoo.com - March 15 at 8:11 AM
OpGen Inc (OPGN) Expected to Post Quarterly Sales of $810,000.00OpGen Inc (OPGN) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - March 14 at 2:52 AM
OpGen (OPGN) Set to Announce Quarterly Earnings on WednesdayOpGen (OPGN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:35 AM
OpGen (OPGN) Cut to "Hold" at Zacks Investment ResearchOpGen (OPGN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:45 AM
OpGen Announces Collaborator in Verification Study for Acuitas® Test - GlobeNewswire (press release)OpGen Announces Collaborator in Verification Study for Acuitas® Test - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:18 AM
OpGen Announces Collaborator in Verification Study for Acuitas® TestOpGen Announces Collaborator in Verification Study for Acuitas® Test
finance.yahoo.com - March 13 at 8:18 AM
OpGen Inc (OPGN) Expected to Post Earnings of -$1.50 Per ShareOpGen Inc (OPGN) Expected to Post Earnings of -$1.50 Per Share
www.americanbankingnews.com - March 12 at 11:08 PM
OpGen (OPGN) Lifted to "Buy" at Zacks Investment ResearchOpGen (OPGN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 10 at 4:20 PM
Head to Head Review: OpGen (OPGN) & Codexis (CDXS)Head to Head Review: OpGen (OPGN) & Codexis (CDXS)
www.americanbankingnews.com - March 8 at 5:11 PM
OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 ... - GlobeNewswire (press release)OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:12 AM
Has OpGen Inc (NASDAQ:OPGN) Improved Earnings Growth In Recent Times?Has OpGen Inc (NASDAQ:OPGN) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 6 at 8:12 AM
OpGen to Present at the Cowen and Company 38th Annual Health Care ConferenceOpGen to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 1 at 5:55 PM
$810,000.00 in Sales Expected for OpGen Inc (OPGN) This Quarter$810,000.00 in Sales Expected for OpGen Inc (OPGN) This Quarter
www.americanbankingnews.com - February 25 at 1:44 AM
Zacks: Analysts Expect OpGen Inc (OPGN) Will Post Earnings of -$1.38 Per ShareZacks: Analysts Expect OpGen Inc (OPGN) Will Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - February 23 at 11:12 PM

SEC Filings

OpGen (NASDAQ:OPGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OpGen (NASDAQ:OPGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OpGen (NASDAQ OPGN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.